Aramchol
(Synonyms: Aramchol; C20-FABAC) 目录号 : GC19435
A fatty acid bile acid conjugate
Cas No.:246529-22-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Aramchol, also known as arachidyl amido cholanoic acid, is a conjugate of arachidic acid and cholic acid . It reduces ex vivo cholesterol crystallization in native human bile and dissolves pre-formed cholesterol crystals in a dose-dependent manner. In vivo, aramchol completely prevents the formation of cholesterol crystals and gallstones in mice fed a lithogenic, high-fat diet. It also prevents lithogenic, high-fat diet-induced fatty liver in mice, rats, and hamsters. Formulations containing aramchol have been investigated clinically for the treatment of non-alcoholic fatty liver disease (NAFLD).
References:
[1]. Gilat, T., Leikin-Frenkel, A., Goldiner, I., et al. Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice Lipids 36(10), 1135-1140 (2001).
[2]. Gilat, T., Leikin-Frenkel, A., Goldiner, I., et al. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC) Hepatology 38(2), 436-442 (2003).
[3]. Safadi, R., Konikoff, F.M., Mahamid, M., et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease Clin. Gastroenterol. Hepatol. 12(12), 2085-2091 (2014).
| Cas No. | 246529-22-6 | SDF | |
| 别名 | Aramchol; C20-FABAC | ||
| Canonical SMILES | C[C@H](CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@@H](NC(CCCCCCCCCCCCCCCCCCC)=O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@@]21C | ||
| 分子式 | C44H79NO5 | 分子量 | 702.1 |
| 溶解度 | DMF: 30 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 20 mg/ml,Ethanol: 20 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4243 mL | 7.1215 mL | 14.243 mL |
| 5 mM | 0.2849 mL | 1.4243 mL | 2.8486 mL |
| 10 mM | 0.1424 mL | 0.7121 mL | 1.4243 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet